Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The VITamin D and OmegA-3 Trial (VITAL; NCT 01169259) is a randomized clinical trial in
25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin
D3 (2000 IU) or omega-3 fatty acids (Omacor fish oil, 1 gram) reduces the risk of developing
cancer, heart disease, and stroke in people who do not have a prior history of these
illnesses. This ancillary study is being conducted among participants in VITAL and will
examine whether vitamin D or omega-3 fatty acids, compared to placebo, reduce the incidence
and/or progression of age-related macular degeneration (AMD).
Phase:
N/A
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
National Eye Institute (NEI)
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins